The University of Chicago Header Logo

Connection

David A. Ehrmann to Polycystic Ovary Syndrome

Back to Details
This is a "connection" page, showing publications David A. Ehrmann has written about Polycystic Ovary Syndrome.
David A. Ehrmann
Connection Strength
10.646
Polycystic Ovary Syndrome
  1. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022 05; 117(5):897-911.
    View in: PubMed
    Score: 0.726
  2. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
    View in: PubMed
    Score: 0.522
  3. Obstructive sleep apnea and polycystic ovary syndrome: cause or association? Sleep Med. 2017 08; 36:170-171.
    View in: PubMed
    Score: 0.503
  4. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
    View in: PubMed
    Score: 0.487
  5. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.362
  6. Metabolic dysfunction in pcos: Relationship to obstructive sleep apnea. Steroids. 2012 Mar 10; 77(4):290-4.
    View in: PubMed
    Score: 0.353
  7. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov; 26(11):3138-46.
    View in: PubMed
    Score: 0.347
  8. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb; 96(2):365-74.
    View in: PubMed
    Score: 0.329
  9. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010 Oct; 24(5):717-30.
    View in: PubMed
    Score: 0.325
  10. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.303
  11. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct; 93(10):3878-84.
    View in: PubMed
    Score: 0.279
  12. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
    View in: PubMed
    Score: 0.271
  13. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar; 50(1):244-54.
    View in: PubMed
    Score: 0.254
  14. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):48-53.
    View in: PubMed
    Score: 0.231
  15. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):36-42.
    View in: PubMed
    Score: 0.230
  16. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
    View in: PubMed
    Score: 0.222
  17. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jan; 90(1):66-71.
    View in: PubMed
    Score: 0.216
  18. Genetic contributions to glucose intolerance in polycystic ovary syndrome. Reprod Biomed Online. 2004 Jul; 9(1):28-34.
    View in: PubMed
    Score: 0.211
  19. Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jun; 89(6):2973-6.
    View in: PubMed
    Score: 0.210
  20. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun; 66(3):356-62.
    View in: PubMed
    Score: 0.208
  21. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.203
  22. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med. 2003 Aug; 21(3):277-83.
    View in: PubMed
    Score: 0.198
  23. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Sep; 87(9):4297-300.
    View in: PubMed
    Score: 0.186
  24. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Apr; 87(4):1669-73.
    View in: PubMed
    Score: 0.180
  25. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002 Feb; 87(2):772-5.
    View in: PubMed
    Score: 0.178
  26. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep. 2002 Feb; 2(1):71-6.
    View in: PubMed
    Score: 0.178
  27. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001 May; 86(5):2027-31.
    View in: PubMed
    Score: 0.169
  28. Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic beta-cell. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1299-301.
    View in: PubMed
    Score: 0.154
  29. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
    View in: PubMed
    Score: 0.148
  30. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan; 22(1):141-6.
    View in: PubMed
    Score: 0.144
  31. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 12; 14(12):e1007813.
    View in: PubMed
    Score: 0.144
  32. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
    View in: PubMed
    Score: 0.142
  33. Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2018 02 01; 103(2):486-496.
    View in: PubMed
    Score: 0.135
  34. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.130
  35. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol. 1997 Jun; 11(2):335-47.
    View in: PubMed
    Score: 0.129
  36. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.126
  37. Hormonal Evaluation of Hyperandrogenism in Women. JAMA. 2015 Dec 15; 314(23):2557-8.
    View in: PubMed
    Score: 0.117
  38. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015 Aug 18; 6:7502.
    View in: PubMed
    Score: 0.114
  39. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.113
  40. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995 Jun; 16(3):322-53.
    View in: PubMed
    Score: 0.112
  41. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.110
  42. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12):4565-92.
    View in: PubMed
    Score: 0.100
  43. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
    View in: PubMed
    Score: 0.100
  44. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.092
  45. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.091
  46. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.073
  47. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 May; 94(5):1587-94.
    View in: PubMed
    Score: 0.073
  48. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.073
  49. Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):270-6.
    View in: PubMed
    Score: 0.058
  50. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
    View in: PubMed
    Score: 0.050
  51. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.048
  52. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1626-32.
    View in: PubMed
    Score: 0.042
  53. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1285-9.
    View in: PubMed
    Score: 0.039
  54. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril. 1999 Aug; 72(2):360-3.
    View in: PubMed
    Score: 0.037
  55. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8573-8.
    View in: PubMed
    Score: 0.037
  56. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci. 1993 May 28; 687:162-81.
    View in: PubMed
    Score: 0.024
  57. Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet. 1999 Aug; 22(4):324-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.